Compare NICE Ltd (NICE) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Zimmer Biomet Holdings Inc — how do they compare? NICE Ltd trades at $117 (market cap $6.81B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.5× NICE Ltd's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while NICE Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold NICE Ltd for 15 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| NICE | ZBH | |
|---|---|---|
Market Cap | $6.81B | $16.95B |
Volume | 382,395 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $137.68 | $103.98 |
52-Week Low | $83.15 | $79.58 |
Typical Hold Time | 15 Days | 89 Days |
Enterprise Value | $6.54B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE Ltd. (NICE) trades at $116.42, up 0.95% on the day, with a bullish technical signal from moving averages. The company shows solid fundamentals with a P/E of 17.08 and strong profitability margins, including a 65.12% gross margin. Recent earnings have consistently beaten expectations, and analyst consensus is bullish with a $124.20 price target. Business developments include being named a leader in IDC MarketScape for contact center platforms, highlighting its competitive position in AI-driven customer experience solutions.
The outlook for NICE is positive, supported by AI-driven growth and a reasonable valuation. Investment opportunities include continued cloud and AI revenue expansion, while risks involve margin compression from heavy investment and market volatility. With no sell ratings from analysts and institutional buying activity, the stock presents a favorable risk-reward profile for growth-oriented investors.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $8.23B in 2025, though net margins have compressed from 13.84% in 2023 to 8.56%. Analyst consensus is mixed with 40% buy ratings but a $103.11 price target suggesting 16.5% upside. Recent news highlights dividend declarations and leadership promotions aimed at accelerating commercial transformation.
ZBH presents a value opportunity with reasonable valuation multiples (P/E 21.48, P/S 2.04) and consistent earnings outperformance, but faces headwinds from margin pressure and technical weakness. The stock's investment case hinges on execution of growth initiatives amid competitive and debt-related risks, with current levels offering entry near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
